Scalper1 News
Gene-tester Myriad Genetics modestly beat fiscal Q4 estimates late Tuesday, but EPS guidance below consensus sent the stock falling 5% in after-hours trading. Revenue for the quarter that ended June 30 rose 8.4% over the year-earlier quarter to $188.8 million, less than $1 million above analysts’ average estimate. Profit declined 9.5% to 48 cents a share, beating consensus by 2 cents. Myriad Genetics (MYGN) guided fiscal 2015 revenue at $800 Scalper1 News
Scalper1 News